Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 242 matching drugs for BTK — including drugs targeting any of its 34 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BTK Direct 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment BTK Direct 2
ibrutinib BTK Direct yes 2
afatinib, dasatinib, palbociclib, everolimus, olaparib BTK Direct 1
bevacizumab, dasatinib, placebo BTK Direct 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride BTK Direct 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method BTK Direct 1
dasatinib, laboratory biomarker analysis, physiologic testing BTK Direct 1
dasatinib, mfolfox6 BTK Direct 1
dasatinib, pharmacological study BTK Direct 1
dasatinib, temozolomide, placebo, radiation therapy BTK Direct 1
ibrutinib, durvalumab BTK Direct 1
ibrutinib, fludarabine BTK Direct 1
ibrutinib, gemcitabine, nab-paclitaxel BTK Direct 1
ibrutinib, indoximod, cyclophosphamide, etoposide BTK Direct 1
ibrutinib, paclitaxel, gemcitabine BTK Direct 1
ibrutinib, radiation, temozolomide (tmz) BTK Direct 1
acalabrutinib BTK Direct yes 0
zanubrutinib BTK Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
olaparib PARP1 SSL via PARP1 yes 1
osimertinib EGFR SSL via EGFR yes 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ALK SSL via ALK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR3 SSL via FGFR3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMO SSL via SMO 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib WEE1 SSL via WEE1 3
crizotinib ALK SSL via ALK yes 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR3 SSL via FGFR3 3
pembrolizumab, belzutifan, lenvatinib FGFR3 SSL via FGFR3 3
adavosertib, radiation therapy WEE1 SSL via WEE1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ALK SSL via ALK 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR3 SSL via FGFR3 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel IGF1R SSL via IGF1R 2
alectinib, stereotactic radiosurgery ALK SSL via ALK 2
bbi-355, erlotinib, futibatinib FGFR3 SSL via FGFR3 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study IGF1R SSL via IGF1R 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study IGF1R SSL via IGF1R 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ALK SSL via ALK 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib JAK2 SSL via JAK2 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC2 SSL via HDAC2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR3 SSL via FGFR3 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK2 SSL via JAK2 2
lenvatinib, pembrolizumab FGFR3 SSL via FGFR3 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR3 SSL via FGFR3 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR3 SSL via FGFR3 2
motexafin gadolinium, radiation therapy RRM2 SSL via RRM2 2
nintedanib FGFR3 SSL via FGFR3 yes 2
nintedanib, pembrolizumab FGFR3 SSL via FGFR3 2
pazopanib FGFR3 SSL via FGFR3 yes 2
pembrolizumab, guadecitabine, mocetinostat HDAC2 SSL via HDAC2 2
pembrolizumab, lenvatinib FGFR3 SSL via FGFR3 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR3 SSL via FGFR3 2
pembrolizumab, sonidegib SMO SSL via SMO 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR3 SSL via FGFR3 2
pentostatin, cyclophosphamide, ss1(dsfv)pe38 - lot 073i0809, ss1(dsfv)pe38 - lot fil129j01 ADA SSL via ADA 2
pharmacological study, romidepsin HDAC2 SSL via HDAC2 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FGFR3 SSL via FGFR3 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide RRM2 SSL via RRM2 1
adavosertib WEE1 SSL via WEE1 1
adavosertib, laboratory biomarker analysis, pharmacological study, radiation therapy WEE1 SSL via WEE1 1
adavosertib, radiation therapy, temozolomide WEE1 SSL via WEE1 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy HDAC2 SSL via HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid HDAC2 SSL via HDAC2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ABL1 SSL via ABL1 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib ALK SSL via ALK 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SMO SSL via SMO 1
atorvastatin, temozolomide, radiotherapy HDAC2 SSL via HDAC2 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab HDAC2 SSL via HDAC2 1
bevacizumab, dasatinib, placebo ABL1 SSL via ABL1 1
bevacizumab, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging FGFR3 SSL via FGFR3 1
biopsy, biospecimen collection, crizotinib, radiologic examination ALK SSL via ALK 1
biopsy, biospecimen collection, echocardiography, radionuclide imaging, vismodegib SMO SSL via SMO 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography FGFR3 SSL via FGFR3 1
bosutinib ABL1 SSL via ABL1 yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FGFR3 SSL via FGFR3 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor HDAC2 SSL via HDAC2 1
ceritinib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis, paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study ALK SSL via ALK 1
chemotherapy, cladribine, radiation therapy RRM2 SSL via RRM2 1
conventional surgery, 3-dimensional conformal radiation therapy, stereotactic radiosurgery, motexafin gadolinium, magnetic resonance imaging, spectroscopy RRM2 SSL via RRM2 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride ABL1 SSL via ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method ABL1 SSL via ABL1 1
dasatinib, laboratory biomarker analysis, physiologic testing ABL1 SSL via ABL1 1
dasatinib, mfolfox6 ABL1 SSL via ABL1 1
dasatinib, pharmacological study ABL1 SSL via ABL1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.